Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074, Aachen, Germany.
DWI - Leibniz Institute for Interactive Materials, RWTH Aachen University, 52074, Aachen, Germany.
Adv Sci (Weinh). 2024 Oct;11(40):e2404385. doi: 10.1002/advs.202404385. Epub 2024 Aug 29.
Microbubbles (MB) are widely used as contrast agents for ultrasound (US) imaging and US-enhanced drug delivery. Polymeric MB are highly suitable for these applications because of their acoustic responsiveness, high drug loading capability, and ease of surface functionalization. While many studies have focused on using polymeric MB for diagnostic and therapeutic purposes, relatively little attention has thus far been paid to improving their inherent imaging and drug delivery features. This study here shows that manipulating the polymer chemistry of poly(butyl cyanoacrylate) (PBCA) MB via temporarily mixing the monomer with the monomer-mimetic butyl cyanoacetate (BCC) during the polymerization process improves the drug loading capacity of PBCA MB by more than twofold, and the in vitro and in vivo acoustic responses of PBCA MB by more than tenfold. Computer simulations and physisorption experiments show that BCC manipulates the growth of PBCA polymer chains and creates nanocavities in the MB shell, endowing PBCA MB with greater drug entrapment capability and stronger acoustic properties. Notably, because BCC can be readily and completely removed during MB purification, the resulting formulation does not include any residual reagent beyond the ones already present in current PBCA-based MB products, facilitating the potential translation of next-generation PBCA MB.
微泡(MB)广泛用作超声(US)成像和 US 增强药物递送的造影剂。由于其声学响应性、高载药能力和易于表面功能化,聚合物 MB 非常适合这些应用。虽然许多研究都集中在使用聚合物 MB 进行诊断和治疗目的上,但到目前为止,相对较少关注改善其固有成像和药物递送特性。本研究表明,通过在聚合过程中临时将单体与单体模拟物丁基氰基乙酸酯(BCC)混合,来操纵聚(正丁基氰基丙烯酸酯)(PBCA)MB 的聚合物化学,可以将 PBCA MB 的载药能力提高两倍以上,并且可以将 PBCA MB 的体外和体内声学响应提高十倍以上。计算机模拟和物理吸附实验表明,BCC 可以操纵 PBCA 聚合物链的生长并在 MB 壳中形成纳米腔,赋予 PBCA MB 更大的药物包封能力和更强的声学特性。值得注意的是,因为在 MB 纯化过程中可以很容易且完全去除 BCC,所以得到的制剂不包括任何残留试剂,除了当前基于 PBCA 的 MB 产品中已经存在的那些试剂,这有利于下一代 PBCA MB 的潜在转化。